    Reid Huber | Incyte Corporation | ZoomInfo.com 



Bellicum Appoints Reid Huber, Ph.D. to Board of Directors | Business Wire


























































Bellicum Appoints Reid Huber, Ph.D. to Board of Directors






November 17, 2014 07:00 AM Eastern Standard Time



HOUSTON--(BUSINESS WIRE)--Bellicum Pharmaceuticals, Inc., a biopharmaceutical company focused on 
      discovering and developing novel cellular immunotherapies, today 
      announced the appointment of Reid M. Huber, Ph.D. to its Board of 
      Directors.
    


      Dr. Huber has over 16 years of experience in pharmaceutical research and 
      clinical development, in both senior leadership and scientific research 
      positions. He currently serves as Executive Vice President and Chief 
      Scientific Officer at Incyte Corporation where he leads drug discovery 
      research primarily in the area of hematology/oncology.
    

      “Dr. Huber has an impressive track record of leading drug discovery 
      research, and a depth of knowledge and understanding of immuno-oncology 
      that is central to several of Bellicum’s clinical programs,” commented 
      Tom Farrell, CEO of Bellicum Pharmaceuticals. “We look forward to the 
      unique perspective Reid can bring to Bellicum as we advance our novel 
      cell therapy product candidates.”
    

      Added Dr. Huber, “I am eager to work closely with fellow Bellicum 
      directors and the management team in helping to achieve the full 
      potential of the Company’s promising controlled-cell therapies.”
    

      Dr. Huber began his career at DuPont Pharmaceuticals in 1998 and was a 
      founding member of the team that started drug discovery at Incyte 
      Corporation in 2002. He received his B.S. in biochemistry/molecular 
      genetics from Murray State University and his Ph.D. in molecular 
      genetics from Washington University, and later trained at the National 
      Institutes of Health.
    

About Bellicum Pharmaceuticals


      Bellicum is a clinical stage biopharmaceutical company focused on 
      discovering and developing novel cellular immunotherapies for various 
      forms of cancer, including hematological cancers and solid tumors, as 
      well as orphan inherited blood disorders. The Company is using its 
      proprietary Chemical Induction of Dimerization, or CID, technology 
      platform to engineer and control components of the immune system in real 
      time. The Company is developing next-generation product candidates in 
      some of the most important areas of cellular immunotherapy, including 
      hematopoietic stem cell transplantation, or HSCT, CAR T cell therapy, 
      and dendritic cell vaccines. For more information, please visit www.bellicum.com.
    




Contacts

Investors:Pete Rahmer, 646-378-2973prahmer@troutgroup.comorMedia:Brad 
      Miles, 646-513-3125bmiles@bmccommunications.comorAmy 
      Bonanno, 646-513-3117abonanno@bmccommunications.com















Contacts

Investors:Pete Rahmer, 646-378-2973prahmer@troutgroup.comorMedia:Brad 
      Miles, 646-513-3125bmiles@bmccommunications.comorAmy 
      Bonanno, 646-513-3117abonanno@bmccommunications.com









 
 

 






Search




Advanced News Search

Advanced News Search













Log In
Sign Up















Insider Trading - Huber Reid M - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Huber Reid M





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Common stock purchase or sale:



TransactionDate
ReportedDate
Company
Symbol
InsiderRelationship
SharesTraded
AveragePrice
TotalAmount
SharesOwned
Filing




2016-11-09Sale
2016-11-104:34 pm
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
2,715
$109.9
$298,514
63,924(Direct)
View


2016-10-07Sale
2016-10-114:37 pm
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
11,709
$96.4
$1,128,748
78,310(Direct)
View


2016-08-02Sale
2016-08-025:09 pm
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
10,000
$87.96
$879,600
66,601(Direct)
View


2015-09-21Sale
2015-09-234:35 pm
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
10,000
$124.3
$1,242,900
72,865(Direct)
View


2015-03-30Sale
2015-04-014:26 pm
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
34,263
$93.66
$3,209,206
78,671(Direct)
View




Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-10-07Exercise
2016-10-114:37 pm
N/AN/A
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
11,709
$18.32
78,310(Direct)
View


2016-10-07Exercise
2016-10-114:37 pm
N/A2020-02-08
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
11,709
$18.32
78,310(Direct)
View


2016-07-15Option Award
2016-07-194:43 pm
N/AN/A
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
5,555
$0
76,601(Direct)
View


2016-07-15Option Award
2016-07-194:43 pm
N/A2026-07-14
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
19,091
$83.83
76,601(Direct)
View


2016-06-15Option Award
2016-06-174:12 pm
N/A2026-06-14
Bellicum Pharmaceuticals Inc
BLCM
Huber Reid MDirector
10,000
$12.44
10,000(Direct)
View


2016-02-16Exercise
2016-02-184:31 pm
N/AN/A
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
5,377
$18.32
71,046(Direct)
View


2016-02-16Exercise
2016-02-184:31 pm
N/A2020-02-08
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
5,377
$18.32
71,046(Direct)
View


2016-01-07Option Award
2016-01-084:37 pm
N/AN/A
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
2,610
$0
65,669(Direct)
View


2016-01-07Option Award
2016-01-084:37 pm
N/A2023-01-06
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
18,198
$95.76
65,669(Direct)
View


2016-01-07Option Award
2016-01-084:37 pm
N/A2023-01-06
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
586
$95.76
65,669(Direct)
View


2016-01-07Option Award
2016-01-084:37 pm
N/A2026-01-06
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
21,170
$95.76
65,669(Direct)
View


2016-01-07Option Award
2016-01-084:37 pm
N/A2026-01-06
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
1,044
$95.76
65,669(Direct)
View


2015-09-21Exercise
2015-09-234:35 pm
N/AN/A
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
10,000
$18.32
72,865(Direct)
View


2015-09-21Exercise
2015-09-234:35 pm
N/A2020-02-08
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
10,000
$18.32
72,865(Direct)
View


2015-08-07Exercise
2015-08-104:29 pm
N/AN/A
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
6,316
$17.79
62,857(Direct)
View


2015-08-07Exercise
2015-08-104:29 pm
N/AN/A
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
2,081
$18.32
62,857(Direct)
View


2015-08-07Exercise
2015-08-104:29 pm
N/A2019-01-18
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
6,316
$17.79
62,857(Direct)
View


2015-08-07Exercise
2015-08-104:29 pm
N/A2020-02-08
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
2,081
$18.32
62,857(Direct)
View


2015-06-17Option Award
2015-06-195:03 pm
N/A2025-06-16
Bellicum Pharmaceuticals Inc
BLCM
Huber Reid MDirector
10,000
$22.63
10,000(Direct)
View


2015-04-16Exercise
2015-04-175:10 pm
N/AN/A
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
675
$17.79
54,460(Direct)
View


2015-04-16Exercise
2015-04-175:10 pm
N/AN/A
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
1,355
$13.34
54,460(Direct)
View


2015-04-16Exercise
2015-04-175:10 pm
N/AN/A
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
8,030
$14.72
54,460(Direct)
View


2015-04-16Exercise
2015-04-175:10 pm
N/A2019-01-18
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
675
$17.79
54,460(Direct)
View


2015-04-16Exercise
2015-04-175:10 pm
N/A2017-05-17
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
1,355
$13.34
54,460(Direct)
View


2015-04-16Exercise
2015-04-175:10 pm
N/A2018-01-24
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
8,030
$14.72
54,460(Direct)
View


2015-03-30Exercise
2015-04-014:26 pm
N/AN/A
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
17,499
$18.32
78,671(Direct)
View


2015-03-30Exercise
2015-04-014:26 pm
N/AN/A
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
16,764
$17.79
78,671(Direct)
View


2015-03-30Exercise
2015-04-014:26 pm
N/A2020-02-08
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
17,499
$18.32
78,671(Direct)
View


2015-03-30Exercise
2015-04-014:26 pm
N/A2019-01-18
Incyte Corp
INCY
Huber Reid MEVP, Chief Scientific Officer
16,764
$17.79
78,671(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Fri, 28 Jul 2017 23:44:00 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  








 












Reid M. Huber, Incyte Corporation Chief Scientific Officer & EVP - REDBOOKS








































Brands, Marketers, Agencies. Search Less. Sell More.





/   SIGN IN

GET A FREE TRIAL   
CONTACT US: (800) 908-5395





















Reid M. Huber
Chief Scientific Officer & EVP, Incyte Corporation

EMAIL: 
                      







              Real-time sales trigger feed - generated by REDBOOKS machine learning and natural language processing technology, tracking 800,000+ news sources to aggregate all new executives, job/role changes and news on decision makers, brands and agencies in the media/marketing industry.
              

              This sales feed is for Reid M. Huber at Incyte Corporation. Reid M. Huber works as Chief Scientific Officer & EVP .  Incyte Corporation is a leader in Pharmaceuticals & Health Care Products .
              REDBOOKS tracks personnel changes for advertisers spending over $1 million annually.
              

              For more  leads or media/marketing prospecting automation, start a free trial now.
              

Recent Related News


07/26/2017:


Innovation Delaware Company to Watch: Incyte

..... What started as work toward a way to combat multiple myeloma and other tumors eventually became a pharmaceutical that tackled myelofibrosis and polycythemia vera, two blood cancers.
“Those were two diseases we didn’t consider when we started,” says Reid Huber, Ph.D., Incyte’s chief scientific officer. “So, with the research we are doing in 2017, we have to have an eye on 2027 and 2030......

People In This Article:
Reid M. Huber
 

05/04/2017:


Incyte (INCY) Q1 2017 Results - Earnings Call Transcript

..... It's Steven again. I will do your first question and then I'll ask Reid Huber to address your second question about LSD1 in sickle cell. In terms of the REACH studies in general and the use of glucocorticoid as a standard initial therapy, the most common used is methylprednisolone is usually used at a dose of 2 milligrams per kilogram in divided doses. .....

People In This Article:
Michael Booth
,                                            Reid M. Huber
 






Learn more about Reid M. Huber  and 260,000+ key contacts

  Create targeted lead lists

  Gain insider knowledge with advanced machine  learning
  Real-time verified contact info



Enter Work Email:

Please enter email address.
 Please enter valid email address.









             Learn more about Reid M. Huber and 260,000+ key contacts
            



























First Name *

 Please enter first name.




Last Name *

 Please enter last name.






Company Name *

 Please enter company name.






Email *





Phone *

 Please enter phone number.
 Please enter 10 digits number.





What industry are you in? *  
                (Please select one the categories below)
Please enter value for the industry.




                     Media Sales
                  




                     Production
                  




                     Ad-Tech/Mar-Tech
                  




                     Sponsorship Sales
                  



  Agency New Business
                  



  Other:
                  




What is your role? *
                 
                 (Please select one the categories below)
Please enter value for the role.



  C-Suite
                  



  VP/Manager
                  



  Sales Rep
                  



  Other:
                  














Thank you for registering for a Free REDBOOKS.com Trial!
We are processing your request and will be in touch shortly to get you started!
For Immediate Assistance, please call us at (800) 908-5395 or email us at info@redbooks.com


























Home
Learn More
FREE Trial


Features




AD THINK Events
Thought Leadership Events
Top Advertiser Directory
Top Agency Directory



Add Your Agency
Update Your Agency
Agency Showcase
Advertising Associations
Creative Spotlight
Services and Suppliers


About Us
Blog
Contact Us
Jobs
Terms & Conditions
Privacy Policy





Customer Support
(800) 908-5395
Connect with us




















Copyright © 2017 Red Books LLC. All rights reserved
































Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft













Incyte Corp : INCY Stock Price Quote at Ally Invest






















Quotes Snapshot > INCYIncyte Corp INCY:NASDAQSet AlertOptionsStreaming Charts

	Next Earnings date is expected on 
	08/01/2017
	Last Price$135.74NASDAQ Previous Close - Last Trade as of 3:59PM ET 7/28/17Today's Change+3.02(2.28%)Bid (Size)$125.55 (1)Ask (Size)$153.33 (1)Day Low / High$132.18 - 136.81Volume990.8  KSellBuySnapshotChartsNewsOptionsEarningsFundamentalsFinancialsInsiders




View advanced chart







Mountain
OHLC
Candlestick
Line


Chart Style

Download historical data





 


View Biotechnology IndustryPeer Comparison as of 07/28/20171 Day5 Day1 Month3 Month1 Year5 Year10 YearTimeframe Incyte Corp ( NASDAQ )Price: $135.74Change: +3.02 (2.28%)Volume: 989.8  K3:59PM ET 7/28/2017 SellBuyDetailed Quote|Set Alert|Options Chain Illumina Inc ( NASDAQ )Price: $174.91Change: +0.58 (0.33%)Volume: 626.9  K3:59PM ET 7/28/2017 SellBuyDetailed Quote|Set Alert|Options Chain Alexion Pharmaceuticals Inc ( NASDAQ )Price: $137.95Change: +4.03 (3.01%)Volume: 2.5  M3:59PM ET 7/28/2017 SellBuyDetailed Quote|Set Alert|Options Chain N/A ( N/A )Price: N/AChange: N/A N/AVolume: N/AN/A SellBuyDetailed Quote|Set Alert|Options Chain Agilent Technologies Inc ( NYSE )Price: $60.09Change: +0.18 (0.30%)Volume: 1.2  M3:59PM ET 7/28/2017 SellBuyDetailed Quote|Set Alert|Options Chain

Read more news
				Recent News
			
Eli Lilly and Incyte's Re-submission of a New Drug Application to the FDA Will be Delayed Beyond 20176:16AM ET 7/25/2017 BenzingaEli Lilly and Company (NYSE:LLY) and Incyte Corporation...Lilly and Incyte Provide Update on Baricitinib6:15AM ET 7/25/2017 PRNewswire
INDIANAPOLIS, July 25, 2017 /PRNewswire/  Eli Lilly and...Incyte Reports First Patient Was Treated In Phase 3 Trial Of Itacitinib For Acute Graft-Versus-Host Disease7:40AM ET 7/20/2017 Benzinga© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Merus Announces First Quarter 2017 Financial Results and Mid-Year Operating Results4:05PM ET 7/11/2017 Globe NewswireBalance sheet strengthened with $120 million upfront payment and an $80 million share purchase from Incyte Corporation for global strategic research collaboration to discover...


View all
				Commentary and Analysis
			
3 Things In Biotech You Should Learn Today: July 28, 20179:00AM ET 7/28/2017 Seeking AlphaBiotech Bonanza: The Next Leg Up3:11PM ET 7/25/2017 Seeking Alpha3 Things In Biotech You Should Learn Today: July 22, 20179:00AM ET 7/22/2017 Seeking AlphaFDA's Flashing Green Light Boosts Novel Drug Approvals2:09PM ET 7/19/2017 Seeking Alpha


Company Profile

Business DescriptionIncyte Corp. is a biopharmaceutical company, which focuses on the discovery, development, development, formulation, manufacturing and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. Its product, Jakafi, a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers. The companywas founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE. View company web site for more detailsAddress1801 Augustine Cut-OffWilmington, Delaware 19803Phone+1.302.498.6700Number of Employees980Recent SEC Filing07/21/20174 Chairman, President & Chief Executive OfficerHervé HoppenotChief Financial Officer & Executive Vice PresidentDavid W. GryskaChief Scientific Officer & Executive VPReid M. HuberChief Medical Officer & Executive Vice PresidentSteven H. Stein





Company Highlights
Price Open$132.60Previous Close$132.7252 Week Range$75.52 - 153.15Market Capitalization$27.8  BShares Outstanding204.8  MSectorHealth TechnologyIndustryBiotechnologyNext Earnings Announcement08/01/2017


Options Summary
Call Open Interest (1d)*Put Open Interest (1d)*Call Volume (1d)*Put Volume (1d)*Put Call Open Interest Ratio (1d)*Put Call Volume Ratio (1d)** Data delayed by up to 15 minutes



View all fundamentalsFundamentals
Price / EarningsN/AEarnings per Share-$0.23Beta vs. S&P 5001.16Revenue$1.1  BNet Profit Margin-8.72%Return on Equity-20.84%






Analyst Ratings as of 07/21/2017Buy16Overweight0Hold5Underweight0Sell0Consensus RecommendationPowered by Factset



 


















Reid M. Huber of Incyte Corp Executive Profile

















 












Welcome!















Company News
Company Site
Premium
Log In


 



















Membership
Home
Portfolio
Stocks
Bonds
Funds
ETFs
CEF
Markets
Tools
Real Life Finance
Discuss





Investing Ideas


Fund Analyst Picks
Picks by Category
Fund Pick Performance
Picks & Pans E-Newsletter
Fund Spy Column
Fund Spy Book
Bond Squad
Fund Video Reports
FundInvestor Newsletter
ETF Investing
Fund Family Experts



Fund Reports


All Fund Analyst Reports
Fund Stewardship Reports



Fund Ratings


Highest-Rated Value
Highest-Rated Growth
Highest-Rated Large-Cap
Highest-Rated Mid-Cap
Highest-Rated Small-Cap
Foreign Fund Standouts
Star Rating Performance
Rating Methodology



Fund Performance


Top 1-Month Performers
Top YTD Performers
Top 1-Year Performers
Top 3-Year Performers
Top 5-Year Performers
Fund Category Returns
Biggest Daily NAV Changes
Closed-End Funds
Exchange-Traded Funds
Quarterly Market Outlook



Fund Screeners


Basic Screeners
Fund Screener
Long-Term Winners
Solid Small-Growth Funds
Conservative Bond Funds

Premium Screeners
Premium Fund Screener
Index Funds
Hidden Gems
Lower-Risk Foreign Funds


Video Center
 
 

 



 



Incyte Corp
 INCY


			Morningstar Rating
		



Add to PortfolioGet E-mail AlertsPrint This PagePDF ReportData QuestionQuoteChartStock AnalysisPerformanceKey RatiosFinancialsValuationInsidersOwnershipFilingsBondsOverviewExecutive CompensationInsider ActivityKey ExecutivesBoard of DirectorsCommittees
 


Key Executives
                > Reid M. Huber
            
Reid M. Huber, Executive Vice President and Chief Scientific Officer



Profile
Connections






Biography



    Reid M. Huber, age 45, has served as Executive Vice President, Chief Scientific Officer since April 2014. Dr. Huber joined Incyte as Associate Director, Applied Technology in January 2002 and held roles of increasing responsibility in both drug discovery and clinical development at Incyte. Prior to joining Incyte, Dr. Huber held scientific research positions with DuPont Pharmaceuticals Company from 1998 to 2002. Dr. Huber held intramural pre-doctoral and post-doctoral fellowships at the National Institutes of Health from 1997-1998. Dr. Huber received his B.S. in biochemistry/molecular genetics from Murray State University and his Ph.D. in molecular genetics from Washington University.
    





Board Membership




Reid M. Huber is not a member of any boards




 


  







We value your feedback. Let us know what you think.













 


Site Directory
Site Map
Our Products












 



 



 




Corrections
Help
Advertising Opportunities
Licensing Opportunities
Glossary
RSS
Mobile Portfolio
Affiliate
Careers 
 


International Sites:
        	Australia
Canada
China
France
Germany
Hong Kong
Italy
The Netherlands
Norway
Spain
U.K.
Switzerland

 




Stocks by:
            Name
|
Ticker
|
Star Rating
|
Market Cap
|
Stock Type
|
Sector
|
Industry



Mutual Funds by:
            Star Rating
|
Investment Style
|
Total Assets
|
Category
|
Top Holdings
|
Top Sectors
|
Symbol / Ticker
|
Name



ETFs by:
            Star Rating
|
Category
|
Total Assets
|
Symbol / Ticker
|
Name



Articles by:
            Title
|
Date
|
Author
|
Collection
|
Interest
|
Popularity



Investment Categories by:
            Topic
|
Sector
|
Key Indicators
|
User Interest
|
Market Cap
|
Industry



Premium Stocks by:
            Name
|
Ticker
|
Star Rating
|
Market Cap
|
Stock Type
|
Sector
|
Industry



Premium Mutual Funds by:
            Star Rating
|
Investment Style
|
Total Assets
|
Category
|
Top Holdings
|
Top Sectors
|
Symbol / Ticker
|
Name



Premium ETFs by:
            Star Rating
|
Category
|
Total Assets
|
Symbol / Ticker
|
Name



Popular Articles by:
            Title
|
Date
|
Author
|
Collection
|
Interest
|
Popularity



Popular Investment Categories by:
            Topic
|
Sector
|
Key Indicators
|
User Interest
|
Market Cap
|
Industry




Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.
        © Copyright  Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. Russell 2000 quote is 10 minutes delayed.
 


 


















Bellicum Appoints Reid Huber, Ph.D. to Board of Directors - Bellicum Pharmaceuticals, Inc.











































































 
Smart weapons for the fight against cancer






Search for:



About Us 

Overview
Management Team
Board of Directors
Clinical Advisory Board
Careers
Contact Us


Product Candidates 

Pipeline
BPX-501
BPX-601
BPX-701
CD19 Program


Technology 

Overview
CaspaCIDe
GoCAR-T
Scientific Literature
Abstracts & Presentations


Clinical Trials 

BPX-501 in Blood Cancers &Inherited Blood Disorders


Investors & Media 

Investor Center Home
News & Events

Press Releases
Events & Presentations


Stock Information

Stock Quote
Stock Chart
Historic Stock Lookup
Analyst Coverage
Investment Calculator


Financial Information

Annual Reports & Proxies
SEC Filings


Corporate Governance

Documents & Charters
Management Team
Board of Directors
Committee Composition


Shareholder Services

Investor FAQ
Contact Investor Relations












Search for:



About Us 

Overview
Management Team
Board of Directors
Clinical Advisory Board
Careers
Contact Us


Product Candidates 

Pipeline
BPX-501
BPX-601
BPX-701
CD19 Program


Technology 

Overview
CaspaCIDe
GoCAR-T
Scientific Literature
Abstracts & Presentations


Clinical Trials 

BPX-501 in Blood Cancers &Inherited Blood Disorders


Investors & Media 

Investor Center Home
News & Events

Press Releases
Events & Presentations


Stock Information

Stock Quote
Stock Chart
Historic Stock Lookup
Analyst Coverage
Investment Calculator


Financial Information

Annual Reports & Proxies
SEC Filings


Corporate Governance

Documents & Charters
Management Team
Board of Directors
Committee Composition


Shareholder Services

Investor FAQ
Contact Investor Relations













Home » Press Releases » Bellicum Appoints Reid Huber, Ph.D. to Board of Directors




Press Releases
Scientific Literature
Abstracts & Presentations






Bellicum Appoints Reid Huber, Ph.D. to Board of Directors  

 Press Releases  



Houston, TX, November 17, 2014 –Bellicum Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the appointment of Reid M. Huber, Ph.D. to its Board of Directors.
Dr. Huber has over 16 years of experience in pharmaceutical research and clinical development, in both senior leadership and scientific research positions. He currently serves as Executive Vice President and Chief Scientific Officer at Incyte Corporation where he leads drug discovery research primarily in the area of hematology/oncology.
“Dr. Huber has an impressive track record of leading drug discovery research, and a depth of knowledge and understanding of immuno-oncology that is central to several of Bellicum’s clinical programs,” commented Tom Farrell, CEO of Bellicum Pharmaceuticals. “We look forward to the unique perspective Reid can bring to Bellicum as we advance our novel cell therapy product candidates.”
Added Dr. Huber, “I am eager to work closely with fellow Bellicum directors and the management team in helping to achieve the full potential of the Company’s promising controlled-cell therapies.”
Dr. Huber began his career at DuPont Pharmaceuticals in 1998 and was a founding member of the team that started drug discovery at Incyte Corporation in 2002. He received his B.S. in biochemistry/molecular genetics from Murray State University and his Ph.D. in molecular genetics from Washington University, and later trained at the National Institutes of Health.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. The Company is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR T cell therapy, and dendritic cell vaccines. For more information, please visit www.bellicum.com.




































Reid M. Huber, Ph.D. - Bellicum Pharmaceuticals, Inc.







































































 
Smart weapons for the fight against cancer






Search for:



About Us 

Overview
Management Team
Board of Directors
Clinical Advisory Board
Careers
Contact Us


Product Candidates 

Pipeline
BPX-501
BPX-601
BPX-701
CD19 Program


Technology 

Overview
CaspaCIDe
GoCAR-T
Scientific Literature
Abstracts & Presentations


Clinical Trials 

BPX-501 in Blood Cancers &Inherited Blood Disorders


Investors & Media 

Investor Center Home
News & Events

Press Releases
Events & Presentations


Stock Information

Stock Quote
Stock Chart
Historic Stock Lookup
Analyst Coverage
Investment Calculator


Financial Information

Annual Reports & Proxies
SEC Filings


Corporate Governance

Documents & Charters
Management Team
Board of Directors
Committee Composition


Shareholder Services

Investor FAQ
Contact Investor Relations












Search for:



About Us 

Overview
Management Team
Board of Directors
Clinical Advisory Board
Careers
Contact Us


Product Candidates 

Pipeline
BPX-501
BPX-601
BPX-701
CD19 Program


Technology 

Overview
CaspaCIDe
GoCAR-T
Scientific Literature
Abstracts & Presentations


Clinical Trials 

BPX-501 in Blood Cancers &Inherited Blood Disorders


Investors & Media 

Investor Center Home
News & Events

Press Releases
Events & Presentations


Stock Information

Stock Quote
Stock Chart
Historic Stock Lookup
Analyst Coverage
Investment Calculator


Financial Information

Annual Reports & Proxies
SEC Filings


Corporate Governance

Documents & Charters
Management Team
Board of Directors
Committee Composition


Shareholder Services

Investor FAQ
Contact Investor Relations













Home » Team Members » Reid M. Huber, Ph.D.




Overview
Management Team
Board of Directors
Clinical Advisory Board
Careers
Contact Us






Reid M. Huber, Ph.D.  




Director

Reid Huber has over 16 years of experience in pharmaceutical research and clinical development, in both senior leadership and scientific research positions. He currently serves as Executive Vice President and Chief Scientific Officer at Incyte Corporation where he leads drug discovery research primarily in the area of hematology/oncology. Dr. Huber began his career at DuPont Pharmaceuticals in 1998 and was a founding member of the team that started drug discovery at Incyte Corporation in 2002. He received his B.S. in biochemistry/molecular genetics from Murray State University and his Ph.D. in molecular genetics from Washington University, and later trained at the National Institutes of Health.































